Today we interview Dr. Ghulam Rehman Mohyuddin of Kansas University Medical Center on his new paper out now in The Lancet Haematology titled "Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review".

Control Groups: doi.org/10.1016/S2352-3026(21)00024-7

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

March 2021

3.56 Quality of Control Groups in RCTs of Multiple Myeloma with Dr. Ghulam Rehman Mohyuddin

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

3.56 Quality of Control Groups in RCTs of Multiple Myeloma with Dr. Ghulam Rehman Mohyuddin

Plenary Session - inactive due to federal service